Loading...

Solasia Pharma K.K.

4597.T•JPX
Healthcare
Drug Manufacturers - Specialty & Generic
¥41.00
¥-3.00(-6.82%)

Solasia Pharma K.K. (4597.T) Stock Overview

Explore Solasia Pharma K.K.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 66.8/100

Key Financials

Market Cap9.9B
P/E Ratio-4.65
EPS (TTM)$-9.77
ROE-1.24%
Fundamental Analysis

AI Price Forecasts

1 Week$31.53
1 Month$34.99
3 Months$43.90
1 Year Target$22.87

4597.T Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Solasia Pharma K.K. (4597.T) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 61.54, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $22.87.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.65 and a market capitalization of 9.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

61.54RSI (14)
2.81MACD
35.67ADX
Revenue Growth
-48.78%
↓ 48.78%
Profit Growth
¥-8.81
↓ 74.55%
EPS Growth
¥-8.81
↓ 47.81%
Operating Margin
-589.36%
↓ 71.29%
ROE
-124.30%
↓ 74.55%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 4597.TAnalyst Recommendations details for 4597.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.

CEO

Yoshihiro Arai

Employees

23

Headquarters

Sumitomo Fudosan Shiba-Koen Tower, Tokyo

Founded

2017

Frequently Asked Questions

;